Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

NCT ID: NCT00416962

Last Updated: 2007-11-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2006-12-31

Brief Summary

This study is designed to assess the safety and pharmacokinetic effects of oseltamivir administration alone or in combination with amantadine in healthy volunteers.

Conditions

Healthy

Keywords

Oseltamivir, amantidine, Symmetrel, Tamiflu

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

amantadine hydrochloride

Intervention Type: DRUG

oseltamivir phosphate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male or female subjects aged 18 to 45 years, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests
• Vital signs within the following ranges:

• oral body temperature 35.0 - 37.5°C
• systolic blood pressure 90 - 140 mm Hg
• diastolic blood pressure 50 - 90 mm Hg
• pulse rate 40 - 90 bpm
• Female subjects of child bearing potential must be using double-barrier local contraception (for example, intra-uterine device plus condom, or spermicidal gel plus condom) or have been surgically sterilized at least 6 months prior before study start, with supportive clinical documentation OR Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion.
• Body mass index must be within 18 - 30 kg/m2. Subjects must weigh at least 50 kg.

Exclusion Criteria

• Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as those who report tobacco use or have a urine cotinine greater than 500 ng/mL
• Female subjects who are pregnant or lactating
• Participation in any clinical investigation involving medical intervention within 4 week prior to study start.
• Donation or loss of ≥ 400 mL of blood within 8 weeks prior to study start, or longer if required by local regulation.
• Significant illness within 2 weeks before study start.
• A past personal or close family medical history of clinically significant ECG abnormalities or of a prolonged QT-interval syndrome.
• History of autonomic dysfunction (for example, history of fainting).
• History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated),
• History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or to similar drugs.
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, or which may jeopardize the subject in case of participation in the study, including bowel, gastrointestinal, renal, pancreatic, hepatic, hematological, immunological, or neurological disorders.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: collaborator

Novartis

INDUSTRY

Sponsor Role: lead

Principal Investigators

Novartis

Role: PRINCIPAL_INVESTIGATOR

Investigator site

Locations

Novartis Investigative Site

East Hanover, New Jersey, United States

Countries

United States

References

Morrison D, Roy S, Rayner C, Amer A, Howard D, Smith JR, Evans TG. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One. 2007 Dec 12;2(12):e1305. doi: 10.1371/journal.pone.0001305.

Reference Type: DERIVED

PMID: 18074029 (View on PubMed)

Other Identifiers

CSYO380A2101

Identifier Type: -

Identifier Source: org_study_id